

## SOUTHEAST ASIA: Changes in tactics as Covid-19 cases spike

New Covid-19 case and fatality numbers continue to set daily records in Indonesia, Thailand, Cambodia, and Myanmar, despite restrictions throughout the region generally being tightened during the past month. Malaysia may also soon exceed its previous peaks. And, more broadly, the fear in these countries is that they have not yet substantially shifted the trajectory of their current outbreaks and could still be weeks away from their worst-case scenarios. Thailand today added more restrictions after Indonesia widened the coverage of its measures this week.

The delta variant is being blamed for the accelerated transmission, but beyond that, domestic conditions vary greatly. Hospitals are overflowing in Jakarta, while the situation is still manageable in Thailand and Malaysia. Myanmar's situation remains highly uncertain, and possibly most at risk in the region, due to disruptions to the healthcare system caused by the civil unrest of the past few months. Despite these varying conditions, some key themes stand out for the next few weeks:

- No longer saved by zero. Countries are quietly shifting their position on tolerable case and fatality levels, stressing the need to allow some economic activity even though this may raise the target trend line of new cases per day. Thailand and Malaysia have practically abandoned the zero or near-zero levels that prevailed for much of last year, while Indonesia and the Philippines are willing to tolerate new daily infections in the high thousands, several times what they would have accepted last year. For some policymakers, hospital capacity, rather than new case numbers, has become their implied near-term marker especially with the growing belief that vaccines help reduce the incidence of serious illness and, consequently, hospitalizations. This may generate some risks in the near term because some healthcare systems are only another spike away from being overburdened. Over the longer term, however, it may help improve the calibration of movement and business restrictions, as higher public and political tolerance for cases would allow governments more leeway in targeting their policies.
- Targeted vaccinations. With vaccine deliveries uneven, variants being a constant threat, and the economic threat from more lockdowns becoming less tenable politically, policymakers in several countries are adjusting their approach to vaccinations. The best-known example is the accelerated vaccination in tourism destinations such as Phuket and Bali to facilitate their reopening. This program could be expanded should the trials succeed and as the peak season, which starts in October, nears. In the Philippines, the lobby in the next few weeks could be for the greater metropolitan Manila area to be vaccinated faster than the rest of the country, not only because of its economic weight, but on the perception that the virus is primarily spread to the rest of the country by travelers from Manila. Cities could therefore receive a disproportionate share of vaccine supplies. Across Southeast Asia, migrant workers, especially those in the construction sector, could similarly be the target of accelerated vaccination to reduce cross-border transmission. However, this could generate internal resentment if non-vaccinated groups experience a marked economic disadvantage in the coming months.
- A booster after Sinovac. Media reports of healthcare workers becoming seriously ill having been inoculated with
  the Sinovac vaccine are generating pressure on governments to plan for booster shots for high-risk populations. But
  governments are wary of openly publicizing their concerns and plans because these may lead to first-time vaccine recipients

**Bob Herrera-Lim** 

Managing Director +1 (646) 561 3514 bob.herreralim@teneo.com avoiding Sinovac, especially since the vaccine is either the main supply or primary backup when other supply falls short in countries such as Indonesia, the Philippines, and Thailand. However, in some cases, misinformation that mRNA vaccines alter recipients' DNA is also leading to a preference for Sinovac in the absence of other alternatives.

Client Portal >>

Bob Herrera-Lim Managing Director +1 (646) 561 3514 bob.herreralim@teneo.com

© 2021 Teneo. All rights reserved. This material was produced by Teneo for use solely by the recipient. This communication is intended as general background research and is not intended to constitute advice on any particular commercial investment or trade matter or issue and should not be relied upon for such purposes. The views expressed here represent opinions as of this date and are subject to change without notice. The information has been obtained from sources believed to be reliable but no guarantees can be given as to its accuracy, completeness or reliability. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic or otherwise, without the prior consent of Teneo.

Teneo Asia 2